Thus far, reports on anti-PD-1 antibody-induced IDDM only focused on pembrolizumab (Keytruda, Merck Sharp & Dohme) and nivolumab (Opdivo, Bristol-Myers Squibb) (Stamatouli et al., 2018; Byun et al., 2020; Kotwal et al., 2019; Clotman et al., 2018; Baden et al., 2018; Gauci et al., 2017; de Filette et al., 2019; Okamoto et al., 2016). The gene discussed is PDCD1; the disease is type 1 diabetes mellitus.